U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Go back to U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens| Gilead Sciences (NASDAQ: GILD) | Delayed: 145.80 +2.08 (1.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.72 | 52 Week High | $108.63 | |||
| Open | $144.26 | 52 Week Low | $71.39 | |||
| Day High | $146.22 | P/E | 80.55 | |||
| Day Low | $143.71 | EPS | $1.81 | |||
| Volume | 1,187,970 | |||||
